• Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology
• Positive opinion is based on comprehensive clinical and non-clinical data that is expected to confirm that Sandoz biosimilar infliximab matches the reference medicine
• This recommendation marks the third CHMP positive opinion granted for a Sandoz biosimilar in 12 months following Erelzi^® and Rixathon^®; Sandoz is on track to launch several biosimilars of major oncology …